Precision Biosciences Financials
This page shows Precision Biosciences (DTIL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Precision BioSciences remains a cash-funded R&D business, with external financing rather than recurring revenue carrying operations.
FY2024’s positive net income was not an operating inflection: the company reported$7.2M of profit while still using$58.4M of operating cash. The return to a-$45.7M net loss in FY2025 shows earnings quality is weak and reported profit can diverge sharply from how much cash the business actually consumes.
Liquidity is strong in the near term: FY2025 cash of
Revenue is not yet setting the expense base: FY2025 revenue fell to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Precision Biosciences's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Precision Biosciences scores -2.55, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($236.3M) relative to total liabilities ($62.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Precision Biosciences passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Precision Biosciences generates $1.44 in operating cash flow (-$65.8M OCF vs -$45.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Precision Biosciences earns $-36.7 in operating income for every $1 of interest expense (-$52.1M vs $1.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Precision Biosciences generated $34.3M in revenue in fiscal year 2025. This represents a decrease of 50.1% from the prior year.
Precision Biosciences's EBITDA was -$50.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 122.7% from the prior year.
Precision Biosciences reported -$45.7M in net income in fiscal year 2025. This represents a decrease of 738.0% from the prior year.
Precision Biosciences earned $-3.56 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 442.3% from the prior year.
Cash & Balance Sheet
Precision Biosciences generated -$65.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 12.3% from the prior year.
Precision Biosciences held $110.8M in cash against $0 in long-term debt as of fiscal year 2025.
Precision Biosciences had 24M shares outstanding in fiscal year 2025. This represents an increase of 193.7% from the prior year.
Margins & Returns
Precision Biosciences's operating margin was -152.2% in fiscal year 2025, reflecting core business profitability. This is down 114.1 percentage points from the prior year.
Precision Biosciences's net profit margin was -133.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 143.9 percentage points from the prior year.
Precision Biosciences's ROE was -49.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 62.3 percentage points from the prior year.
Capital Allocation
Precision Biosciences invested $54.2M in research and development in fiscal year 2025. This represents a decrease of 9.0% from the prior year.
Precision Biosciences invested $85K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 66.0% from the prior year.
DTIL Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.8M-68.3% | $34.2M+163.1% | $13.0M+72122.2% | $18K-37.9% | $29K-95.5% | $638K+10.8% | $576K-98.8% | $49.9M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $13.1M-9.4% | $14.5M-99.9% | $13.4B+104473.9% | $12.8M-6.0% | $13.6M-14.6% | $15.9M+21.6% | $13.1M-24.0% | $17.2M |
| SG&A Expenses | $6.8M-5.9% | $7.2M-99.9% | $7.3B+80189.3% | $9.1M+6.7% | $8.6M-10.7% | $9.6M+9.2% | $8.8M+2.8% | $8.5M |
| Operating Income | -$9.1M-172.6% | $12.5M+100.1% | -$20.7B-94369.1% | -$21.9M+1.1% | -$22.1M+11.0% | -$24.8M-16.8% | -$21.3M-188.1% | $24.1M |
| Interest Expense | $311K-10.6% | $348K-99.9% | $362.0M+101017.3% | $358K+1.1% | $354K-9.7% | $392K+53.1% | $256K-54.3% | $560K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$18.4M-191.6% | $20.1M+100.1% | -$21.8B-92468.0% | -$23.5M-14.4% | -$20.6M-15.9% | -$17.7M-8.0% | -$16.4M-150.2% | $32.7M |
| EPS (Diluted) | $-0.75 | N/A | $-1.84+13.6% | $-2.13+3.6% | $-2.21 | N/A | $-2.25-148.2% | $4.67 |
DTIL Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $143.9M-6.8% | $154.4M-99.8% | $93.5B+85745.7% | $108.9M-12.4% | $124.4M-8.8% | $136.4M-11.0% | $153.3M-7.6% | $165.8M |
| Current Assets | $108.7M-8.5% | $118.7M-99.8% | $51.7B+73492.0% | $70.3M-14.4% | $82.1M-13.6% | $95.0M-14.1% | $110.5M-23.3% | $144.0M |
| Cash & Equivalents | $99.4M-10.3% | $110.8M-99.8% | $44.9B+71989.6% | $62.2M-19.4% | $77.2M-10.1% | $85.9M-13.0% | $98.8M-20.1% | $123.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $4.0M | $0-100.0% | $4.0M | $0-100.0% | $4K-98.3% | $229K+21.8% | $188K-9.2% | $207K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $67.8M+9.0% | $62.2M-99.9% | $76.9B+102573.8% | $74.9M-0.3% | $75.1M-6.2% | $80.0M-9.5% | $88.4M-3.0% | $91.1M |
| Current Liabilities | $7.8M-13.0% | $8.9M-99.9% | $15.0B+110424.8% | $13.6M+9.5% | $12.4M-17.3% | $15.0M+25.0% | $12.0M-63.6% | $33.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $76.1M-17.5% | $92.2M-99.4% | $16.6B+48746.0% | $34.1M-31.0% | $49.3M-12.5% | $56.4M-13.1% | $64.9M-13.2% | $74.7M |
| Retained Earnings | -$546.6M-3.5% | -$528.2M+99.9% | -$548.3B-104034.8% | -$526.5M-4.7% | -$503.0M-4.3% | -$482.5M-3.8% | -$464.7M-3.7% | -$448.3M |
DTIL Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.9M-6.1% | -$11.3M+99.9% | -$15.3B-75229.3% | -$20.3M-6.4% | -$19.1M-2.0% | -$18.7M-216.0% | -$5.9M+60.2% | -$14.9M |
| Capital Expenditures | $18K-5.3% | $19K | $0-100.0% | $2K-96.9% | $64K-34.0% | $97K+148.7% | $39K+39.3% | $28K |
| Free Cash Flow | -$12.0M-6.1% | -$11.3M+99.9% | -$15.3B-75221.9% | -$20.3M-6.1% | -$19.1M-1.8% | -$18.8M-215.6% | -$6.0M+60.1% | -$14.9M |
| Investing Cash Flow | -$114K+64.9% | -$325K-101.9% | $17.0M+141766.7% | -$12K+96.2% | -$314K-223.7% | -$97K-51.6% | -$64K-128.6% | -$28K |
| Financing Cash Flow | $745K-99.0% | $77.5M-95.3% | $1.7B+31201.9% | $5.3M-50.4% | $10.7M+80.5% | $5.9M+58.6% | $3.7M+431.8% | $702K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
DTIL Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -83.7%-120.3pp | 36.6%+159013.5pp | -158976.9%-37438.0pp | -121538.9%-45290.6pp | -76248.3%-72353.9pp | -3894.4%-200.8pp | -3693.6%-3742.0pp | 48.4% |
| Net Margin | -170.2%-229.0pp | 58.9%+167535.8pp | -167476.9%-36810.3pp | -130666.7%-59752.9pp | -70913.8%-68132.4pp | -2781.3%+70.2pp | -2851.6%-2917.2pp | 65.6% |
| Return on Equity | -24.2%-46.1pp | 21.8%+152.7pp | -130.9%-61.8pp | -69.1%-27.4pp | -41.7%-10.2pp | -31.5%-6.1pp | -25.3%-69.2pp | 43.8% |
| Return on Assets | -12.8%-25.9pp | 13.0%+36.3pp | -23.3%-1.7pp | -21.6%-5.1pp | -16.5%-3.5pp | -13.0%-2.3pp | -10.7%-30.5pp | 19.8% |
| Current Ratio | 14.02+0.7 | 13.32+9.9 | 3.45-1.7 | 5.18-1.4 | 6.62+0.3 | 6.34-2.9 | 9.22+4.9 | 4.37 |
| Debt-to-Equity | 0.89+0.2 | 0.67-3.9 | 4.62+2.4 | 2.20+0.7 | 1.52+0.1 | 1.42+0.1 | 1.36+0.1 | 1.22 |
| FCF Margin | -110.3%-77.4pp | -33.0%+117428.6pp | -117461.5%-4833.8pp | -112627.8%-46710.5pp | -65917.2%-62973.7pp | -2943.6%-1910.4pp | -1033.2%-1003.3pp | -29.8% |
Similar Companies
Frequently Asked Questions
What is Precision Biosciences's annual revenue?
Precision Biosciences (DTIL) reported $34.3M in total revenue for fiscal year 2025. This represents a -50.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Precision Biosciences's revenue growing?
Precision Biosciences (DTIL) revenue declined by 50.1% year-over-year, from $68.7M to $34.3M in fiscal year 2025.
Is Precision Biosciences profitable?
No, Precision Biosciences (DTIL) reported a net income of -$45.7M in fiscal year 2025, with a net profit margin of -133.4%.
What is Precision Biosciences's EBITDA?
Precision Biosciences (DTIL) had EBITDA of -$50.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Precision Biosciences's operating margin?
Precision Biosciences (DTIL) had an operating margin of -152.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Precision Biosciences's net profit margin?
Precision Biosciences (DTIL) had a net profit margin of -133.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Precision Biosciences's return on equity (ROE)?
Precision Biosciences (DTIL) has a return on equity of -49.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Precision Biosciences's free cash flow?
Precision Biosciences (DTIL) generated -$65.9M in free cash flow during fiscal year 2025. This represents a -12.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Precision Biosciences's operating cash flow?
Precision Biosciences (DTIL) generated -$65.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Precision Biosciences's total assets?
Precision Biosciences (DTIL) had $154.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Precision Biosciences's capital expenditures?
Precision Biosciences (DTIL) invested $85K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Precision Biosciences spend on research and development?
Precision Biosciences (DTIL) invested $54.2M in research and development during fiscal year 2025.
What is Precision Biosciences's current ratio?
Precision Biosciences (DTIL) had a current ratio of 13.32 as of fiscal year 2025, which is generally considered healthy.
What is Precision Biosciences's debt-to-equity ratio?
Precision Biosciences (DTIL) had a debt-to-equity ratio of 0.67 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Precision Biosciences's return on assets (ROA)?
Precision Biosciences (DTIL) had a return on assets of -29.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Precision Biosciences's cash runway?
Based on fiscal year 2025 data, Precision Biosciences (DTIL) had $110.8M in cash against an annual operating cash burn of $65.8M. This gives an estimated cash runway of approximately 20 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Precision Biosciences's Altman Z-Score?
Precision Biosciences (DTIL) has an Altman Z-Score of -2.55, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Precision Biosciences's Piotroski F-Score?
Precision Biosciences (DTIL) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Precision Biosciences's earnings high quality?
Precision Biosciences (DTIL) has an earnings quality ratio of 1.44x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Precision Biosciences cover its interest payments?
Precision Biosciences (DTIL) has an interest coverage ratio of -36.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Precision Biosciences?
Precision Biosciences (DTIL) scores 53 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.